However, we were unable to conclusively demonstrate that CBP/p300 inhibition promotes SCLC transformation in conjunction with loss of p53 and RB in EGFR-TKI-treated EGFR-mutant LUAD cells as hypothesized. This evidence concerns the gene TP53 and small cell lung carcinoma.